Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Brief Summary: To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.


Options:
A: Arm Label: Arm I (rituximab, bendamustine hydrochloride); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine Hydrochloride, Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm II (ibrutinib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Arm Label: Arm III (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Bendamustine Hydrochloride; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride) | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Aspiration; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Biopsy; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm III (ibrutinib, rituximab)
B: Arm Label: Cohort 1: Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 1a (China only): Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1a (China only): Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 2: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 3: Venetoclax + Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib, Drug: Venetoclax | Intervention Type: DRUG; Name: Zanubrutinib; Assigned to Arm(s): Cohort 1: Zanubrutinib, Cohort 1a (China only): Zanubrutinib, Cohort 2: Zanubrutinib, Cohort 3: Venetoclax + Zanubrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Cohort 3: Venetoclax + Zanubrutinib
C: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
D: Arm Label: Treatment Arm A: Ibrutinib and Venetoclax (I+VEN); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Venetoclax, Drug: Ibrutinib (as Subsequent Therapy) | Arm Label: Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab, Drug: Ibrutinib (as Subsequent Therapy) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Ibrutinib (as Subsequent Therapy); Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN), Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)

Answer: B